AstraZeneca has officially opened its active pharmaceutical ingredient (API) manufacturing facility in Dublin. 

This new facility demonstrates how advanced automation, AI, and innovative new technologies push the boundaries of science and manufacturing.

It was developed with the support and collaboration of Ireland’s investment agency, IDA Ireland. 

'Strengthen our healthcare and biopharma base'

Taoiseach Micheál Martin said: “Investments like this state-of-the-art new manufacturing facility strengthen our healthcare and biopharma base, support high-quality employment, and help ensure medicines can be supplied to patients around the world. It is a significant vote of confidence in Ireland’s life sciences ecosystem and in the highly skilled people who work across the sector.”  

Pam Cheng, executive vice president, global operations, IT & chief sustainability officer, AstraZeneca, said: “This cutting-edge API commercialisation facility is an innovative and unique asset in our global operations network, and plays a key role in the development and launch of our new medicines across our oncology portfolio and beyond. 

"Through advanced automation, AI and innovative new technologies, we’re pushing the boundaries of science and manufacturing – enhancing speed, flexibility, and sustainability to deliver future therapies to patients." 

Michael Lohan, CEO of IDA Ireland, said: “Healthcare and biopharma remain a key growth driver within IDA Ireland’s strategy, and investments like this new API facility underline Ireland’s strength in advanced manufacturing, innovation and talent.

"We are delighted to support AstraZeneca as it continues to expand its operations in Dublin, creating high-value jobs and strengthening the resilience of global supply chains while delivering life-changing medicines for patients worldwide.”